Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Intradiscal Cell Therapy IDCT in adults with single-level, mild to moderate, symptomatic lumbar degenerative disc disease DDD affecting the L3 to S1 spinal discs. This Phase III, randomized, double-blind, sham-controlled, multi-center study aims to compare the effects of IDCT against a sham procedure over a total of 104 weeks, including a 52-week primary period followed by a 52-week follow-up. The study involves approximately 162 adult participants aged 18 to 75 years, who have chronic low back pain unresponsive to conservative treatments and meet specific imaging and clinical criteria. Participants are randomly assigned in a 21 ratio to receive either a single intradiscal injection of 1 mL containing 9,000,000 cellsmL of IDCT into the target disc or a sham needle insertion up to the annulus of the same disc. The target disc is identified as one of L3L4, L4L5, or L5S1, based on imaging reviewed by a central radiologist. Screening includes baseline MRI and X-ray imaging and assessments to confirm eligibility. Randomization occurs 7 to 14 days before the treatment administration. The study includes ongoing monitoring and assessments throughout both the primary treatment and follow-up periods. During the study, participants undergo regular evaluations including pain measurement using the Visual Analogue Scale VAS, disability assessment with the Oswestry Disability Index ODI, quality of life questionnaires EQ-5D, and imaging to assess disc volume. Safety is closely monitored through tracking of adverse events and adverse events of special interest from day 1 through week 104. Additional measures such as pain medication use, concomitant therapies, and treatment failure rates are recorded. Participants are expected to comply with study protocols and attend scheduled visits throughout the two-year study duration.
Actively Recruiting
This research evaluates strategies to improve follow-up care after hospital stays for children with bronchiolitis, an acute lung condition. It focuses on comparing two different multi-component approaches intended to increase as-needed PRN follow-up prescriptions by hospital doctors and reduce unnecessary routine follow-up visits by families. The study is led by Seattle Childrens Hospital and addresses a common practice that may often result in unnecessary visits. Participants are divided into three groups those experiencing a moderate-resource implementation strategy, a high-resource implementation strategy, or no intervention as concurrent controls. The moderate-resource strategy involves educational outreach with family materials, audit and feedback on clinician performance, and clinical decision support tools. The high-resource strategy adds small-group facilitation and expert coach-led support on top of the moderate components. Concurrent control hospitals do not receive any intervention but still collect data. During the study, researchers will track adoption of PRN follow-up prescribing within 7 days after hospital discharge and monitor sustainment of these practices. Families and clinicians will be involved in decision-making supported by educational materials. The study will observe how these strategies affect follow-up visit attendance and clinical practice over time, aiming to optimize care for children hospitalized with bronchiolitis. The study runs from November 2025 to December 2029 for children aged up to 24 months.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the safety and pain relief effects of the ReneuRx device compared to corticosteroid injections in adults aged 22 to 80 who suffer from moderate to severe chronic lateral hip pain associated with Greater Trochanteric Pain Syndrome. This trial aims to understand how the nerve selective therapy device performs against standard treatment in easing hip pain. The study is randomized and controlled, focusing on treatment outcomes and safety over time. Participants will be randomly assigned to receive either the ReneuRx device injection around the femoral nerve branches or a single corticosteroid injection consisting of 40mg Triamcinolone acetate mixed with saline. The treatment is administered once, and participants will be followed closely during the study period. The trial compares these two interventions in parallel groups to assess their analgesic performance and monitor any side effects. During the study, participants will attend scheduled visits and complete quality of life and pain questionnaires over a follow-up period of about 6 to 12 months. Researchers will measure primary effectiveness at 3 months post-treatment and continue to monitor safety for an average of 12 months. Various secondary effectiveness assessments will be conducted at multiple time points up to 12 months. This comprehensive monitoring includes patient-reported outcomes to understand improvements and any adverse events throughout the study.